Results from an analysis that compared outcomes among 4 drugs acting as osteoclast inhibitors among patients receiving treatment for multiple myeloma (MM) show that 5-year risks of osteonecrosis ...

To reflect the proven efficacy and US Food and Drug Administration (FDA) approval of new types of agents (including osteoclast inhibitors such as denosumab), the guideline was updated in 2011.